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Epigenetic alterations in skin 
homing  CD4+CLA+ T cells of atopic 
dermatitis patients
Nathalie Acevedo1,11*, Rui Benfeitas2, Shintaro Katayama3, Sören Bruhn4, Anna Andersson4, 
Gustav Wikberg5, Lena Lundeberg5, Jessica M. Lindvall2, Dario Greco6,7,8, Juha Kere3, 
Cilla Söderhäll3,9 & Annika Scheynius1,10*
T cells expressing the cutaneous lymphocyte antigen (CLA) mediate pathogenic inflammation in 
atopic dermatitis (AD). The molecular alterations contributing to their dysregulation remain unclear. 
With the aim to elucidate putative altered pathways in AD we profiled DNA methylation levels and 
miRNA expression in sorted T cell populations  (CD4+,  CD4+CD45RA+ naïve,  CD4+CLA+, and  CD8+) from 
adult AD patients and healthy controls (HC). Skin homing  CD4+CLA+ T cells from AD patients showed 
significant differences in DNA methylation in 40 genes compared to HC (p < 0.05). Reduced DNA 
methylation levels in the upstream region of the interleukin-13 gene (IL13) in  CD4+CLA+ T cells from 
AD patients correlated with increased IL13 mRNA expression in these cells. Sixteen miRNAs showed 
differential expression in  CD4+CLA+ T cells from AD patients targeting genes in 202 biological processes 
(p < 0.05). An integrated network analysis of miRNAs and CpG sites identified two communities of 
strongly interconnected regulatory elements with strong antagonistic behaviours that recapitulated 
the differences between AD patients and HC. Functional analysis of the genes linked to these 
communities revealed their association with key cytokine signaling pathways, MAP kinase signaling 
and protein ubiquitination. Our findings support that epigenetic mechanisms play a role in the 
pathogenesis of AD by affecting inflammatory signaling molecules in skin homing  CD4+CLA+ T cells and 
uncover putative molecules participating in AD pathways.
Atopic dermatitis (AD) is a common chronic inflammatory skin disorder characterized by intense pruritus and 
xerosis that usually concur with allergic sensitization and elevated plasma immunoglobulin E (IgE)  levels1. In 
recent years, epigenetic modifications are being recognized as key players in the alterations leading to complex 
inflammatory diseases including  AD2–7. By affecting DNA methylation and non-coding RNA levels, these epi-
genetic modifications determine a complex network of chemical signatures that regulate mRNA expression and 
are heritable to daughter cells. Therefore, they control the activation or silencing of genes that are critical for cell 
memory and homeostasis, by regulating which genes are expressed, when, and  where8. DNA methylation is an 
epigenetic modification involving the addition of a methyl group in a cytosine preceding a guanine (CpG site); 
usually when gene promoters are methylated the gene transcription is suppressed while reduced methylation 
levels activate genes and promote their expression. When CpG sites have significant differences in DNA meth-
ylation between patients and controls, they are named differentially methylated probes (DMPs), and if many of 
them are close to each other in a gene it is defined as a differentially methylated region (DRM). The contribution 
of this epigenetic modification in AD has been evaluated in diverse tissues, for instance, DNA methylation in the 
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interleukin 4 receptor gene (IL4R) as detected in cord blood samples was associated with AD at age 12  months9. 
Decreased methylation in the thymic stromal lymphopoietin (TSLP) promoter resulting in TSLP overexpres-
sion has been detected in lesional skin biopsies of AD  patients10. DNA methylation differences have also been 
detected in the epidermis of AD  patients11. Altered expression of microRNAs has also shown to play a crucial 
role in type 2 immunity and in promoting pathogenic mechanisms in  AD12–15. However, very few studies have 
analyzed these epigenetic signatures in purified immune cells from AD  patients3.
Circulating T cells can infiltrate human skin as a mechanism of immunosurveillance. They are identified by 
the expression of the cutaneous lymphocyte-associated antigen (CLA), a cell surface glycoprotein that interacts 
with E-selectin on the endothelium of postcapillary venules and allows their selective transmigration from the 
peripheral circulation to the  dermis16. AD patients have a higher percentage of circulating  CLA+ T cells com-
pared to  HC17,18 and the selective expansion of  CLA+ T cells in severe AD involves populations with Th2 and 
Th22  profiles19. Indeed, the frequencies of  CLA+ Th2 T cells were similarly expanded across all AD age groups 
compared with control  subjects20,21.  CLA+ T cells in the peripheral blood of patients with AD are also functionally 
disturbed, with increased expression of cytokine receptors that promote their Th2-skewed  pattern19. Moreover, 
they induce IgE production in B cells, enhance eosinophil  survival22 and display features of in vivo activation 
such as the spontaneous release of IL-13 and increased levels of CD25, CD40L and HLA-DR23. Circulating 
 CD4+CLA+ T cells in patients with acute AD furthermore produce significantly higher levels of IL-4, IL-13 and 
tumor necrosis alpha compared to patients with chronic AD or healthy controls (HC)24. After skin homing, the 
 CLA+ T cells form dermal infiltrates, secrete interferon gamma and become protected from activation-induced 
cell  death25. Recent studies indicate that circulating  CLA+ T cells share phenotype, function, and clonotypes 
with tissue resident  CLA+ T cells in the  skin26 in agreement with that blood  CD4+CLA+ T cells are a reliable 
surrogate marker of the inflammatory events occurring in the  skin16,27. It has also been observed that interac-
tion with external signals from allergens or the skin microbiome can activate  CLA+ T cells and promote their 
pro-inflammatory  state28. Indeed,  CLA+ T cells are memory cells and antigen-experienced, so they can recognize 
epitopes in airborne and food  allergens29–32 as well as in Staphylococcus aureus18,33.
Even though the alterations in  CLA+ T cells from AD patients are well  documented34 their extensive molecular 
characterization, needed to clarify the pathogenesis of AD, is currently missing. Here we compared genome-
wide DNA methylation levels and miRNA expression in four sorted blood lymphocyte populations  (CD4+, 
 CD4+CD45RA+ naïve,  CD4+CLA+ and  CD8+) isolated from AD patients and HC. This study shows for the first 
time that skin-homing  CD4+CLA+ memory T cells from AD patients contain dysregulated epigenetic signa-
tures, including differences in DNA methylation in 40 protein-coding genes and 16 differentially expressed 
miRNAs. An analysis integrating the coordinated response in miRNAs and CpG probes revealed two groups 
with strong antagonistic behaviors that recapitulated the differences between AD patients and HC. Functional 
analysis of the genes linked to these groups revealed their association with key cytokine signaling pathways and 
protein ubiquitination. Our findings support that epigenetic mechanisms play a role in the pathogenesis of AD 
by affecting inflammatory signaling molecules in skin-homing  CD4+CLA+ memory T cells and reveal novel 
disease candidates.
Results
Purity of isolated T cell populations. Based on our previous observations that sorting by cell-type is 
crucial for the interpretation of results derived from DNA methylation  studies35,36, we isolated four populations 
of peripheral blood lymphocytes  (CD4+,  CD4+CD45RA+ naïve,  CD4+CLA+ and  CD8+ from AD patients with 
severe phenotype and HC (Table 1). The mean cell surface expression of CD4 and CD8 markers was over 90% in 
the respective sorted fractions (Supplementary Table S1 online). The mean CD45RA expression was 90% in the 
sorted naïve cells. The  CD45RO+ marker was expressed on 85% of the sorted  CD4+CLA+ lymphocytes, confirm-
ing their phenotype as memory cells. After cell isolation, we found no significant differences in the mean pro-
portions of sorted positive cells between AD patients and HC (t-test p > 0.05, Supplementary Table S1 online).
Table 1.  Descriptive characteristics of the participants at 450 ml blood donation. a Given the sample size and 
to avoid confounding effects by gender, only males were analyzed. b SCORAD: SCORing Atopic Dermatitis. 
Moderate eczema (score 15 to 40); severe eczema (> 40); n.a = not applicable. c Determined by ImmunoCAP 
(Thermo Fisher, Uppsala, Sweden). Reference value in this population is 122 kUA/L; IQR = interquartile range. 
d Phadiatop = analyses of IgE antibodies in plasma to a mix of aeroallergens including birch, timothy, mugwort, 
mite, cat, dog, horse and mold (Thermo Fisher). e The presence of physician-diagnosed asthma and/or rhinitis 
was obtained by questionnaire at the time of blood sampling.
Healthy controls AD patients
Sample size (n)a 10 10
Age, years (average ± SD) 37 ± 13.9 34.9 ± 14.7
SCORAD (objective)b n.a 44 ± 5.5
Total plasma IgE  kUA/L, (median, IQR)c 16.5 (8.2 – 22.5) 1750 (725 – 3050)
Phadiatop ≥ 0.35 kU /L, (n)d 1/10 10/10
Asthma, yes (n)e 0/10 4/10
Rhinitis, yes (n)e 0/10 10/10
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Comparative analysis of DNA methylation between AD patients and HC. The analysis of 
the genome-wide DNA methylation levels in the four sorted T cell populations revealed that skin-homing 
 CD4+CLA+ T cells were the subset with the largest numbers of differentially methylated CpG probes (DMPs, 
n = 49) between AD patients and HC (Fig. 1a). These cells expressed the  CD3+ marker, as well as the  CLA+ and 
the  CD45RO+ markers, and in about 60% of the population the CCR4 receptor (Fig. 1b). The 49 DMPs in these 
circulating  CD4+CLA+ T cells (BH corrected p value < 0.05) mapped to 35 genes (Table 2). Further analysis of 
DMRs revealed 5 genes with more than 3 DMPs in the  CD4+CLA+ T cells of the AD patients compared to HC 
(Table 3). These results refined the signals detected in GPR55, MAN1A1 and CDHR3 by using the DMP analysis 
(Table 2) and uncovered methylation differences in the genes encoding the transcription factor estrogen recep-
tor alpha (ESR1) and the nuclear receptor co-repressor 2 (NCOR2) (Table 3), suggesting that in AD patients the 
epigenome of circulating  CD4+CLA+ T cells is affected in regions encoding transcription factors. The annotated 
list of 40 differentially methylated genes between AD patients and HC with their cell location and known func-
tion are presented in Table 4.   
Some of the differentially methylated genes in  CD4+CLA+ T cells of AD patients are implicated as key regu-
lators of cytokine signaling pathways and immune inflammation (ARHGEF3, ASB2, DAPP1, IL10RA, PDE4A, 
SH2B3, STIM1 and TOX2, Fig. 1c). We also found that  CD4+CLA+ T cells from AD patients have significantly 
decreased methylation in the IL13 promoter (Fig. 2). DNA methylation levels at the CpG site cg14523284 in 
the upstream region of IL13 were significantly lower compared to the levels in HC (Fig. 2a), by contrast, mRNA 
levels for IL13 were increased in AD patients (Fig. 2b). Spearman correlation tests showed a significant inverse 
correlation between DNA methylation and IL13 mRNA levels (Spearman rho −0.63, p = 0.006) (Fig. 2c), mainly 
driven by AD cases. This CpG site with reduced methylation levels in AD patients was at the proximal upstream 
of the Th2-specific DNA hypersensitive site in the IL13 promoter but within the Th2 locus-control long non-
coding  RNA37 (Fig. 2d), indicating that this epigenetic modification might functionally explain the augmented 
capability of  CD4+CLA+ T cells of AD patients to produce IL-13. Correlations computed within each group 
further strengthen the distinct AD vs HC responses, showing a clear trend within the former group (Spearman 
rho < −0.92, p < 0.0002, FDR < 0.003, n = 10) but no statistically significant relationship in the latter (Spearman 
rho = 0.39, p > 0.38, FDR > 0.38, n = 7). A linear regression to each of the two datasets shows a statistically signifi-
cant relationship between delta-Ct and M-value in AD (p < 0.0005,  R2 > 0.82) but not in HC (p > 0.65,  R2 < 0.05) 
(Fig. 2c).
miRNA deregulation in  CD4+CLA+ T cells of AD patients. The analysis of global miRNA expression 
levels in the four T cell populations revealed that only the  CD4+CLA+ T cells contain differentially expressed 
miRNAs (n = 16) between AD patients and HC (BH corrected p value < 0.05). In AD patients, 10 miRNAs were 
up-regulated, and 6 miRNAs were down-regulated, allowing a clear distinction between AD patients and HC 
(Fig. 3a). We selected 8 differentially expressed miRNAs from the microarray analysis (miR-7-5p, miR-21-3p, 
miR-93-5p, miR-130b-3p, miR-145-5p, miR-150-5p, miR-181b-5p and miR-1275) for technical validation by 
qPCR. Significant differences between AD patients and HC could be confirmed by qPCR for four of them, miR-
21-3p, miR-130b-3p, miR-150-5p and miR-1275 (Fig. 3b,c). Next, we performed gene set enrichment analysis on 
the predicted miRNA targets of upregulated and downregulated miRNAs in AD (Fig. 4) and found 202 biologi-
cal processes associated with the targets of the miRNAs dysregulated in AD (Supplementary Table S2 online). 
The top pathways (FDR < 1.1 × 10−5) included cell differentiation and migration, apoptosis ubiquitin-dependent 
protein catabolic process, transforming growth factor beta receptor signaling pathway and positive regulation of 
MAP kinase activity. We found that ESR1, NDFIP2, ASB2 and TNRC6A genes which were differentially methyl-
ated in AD patients (Table 4) were also targeted by upregulated miRNAs in AD patients (Supplementary Table S2 
online), suggesting complex interactions between these epigenetic layers.
Network analysis of coordinated epigenetic responses reveals potentially perturbed path-
ways in circulating  CD4+CLA+ T cells from AD patients. To further explore the coordinated epige-
netic relationships, we performed network analysis using the full set of miRNAs, as well as the top ~ 1% CpG 
sites showing the largest differences between AD and HC. An association analysis (absolute Spearman ρ > 0.75, 
FDR < 0.001) was used to identify strongly interconnected communities of miRNA/CpG sites. Communities 
are sets of miRNA/CpG sites that tend to display globally coordinated expression patterns, thus highlighting 
potentially harmonized regulatory  effectors38. Importantly, the set of miRNA/CpG sites within a community are 
more strongly associated with their respective community than between communities. Our analyses highlighted 
six communities based on the global coordinated associations between miRNA and CpG sites. Interestingly, we 
identified one miRNA/CpG community (C5) that recapitulated the genes showing significant differences in the 
AD group (Fig. 5a). This community has 640 elements: 122 miRNAs and 518 CpG sites that included 8 out of 12 
CpG sites with increased DNA methylation in AD patients (Table 2) but none with decreased methylation. This 
community also contained all 10 miRNAs that had been identified as upregulated in the AD group by the differ-
ential expression analysis (Fig. 3a), suggesting that our approach was powered enough to capture AD associated 
features and its neighbors including three miRNAs targeting IL13 (hsa-miR-98-5p, hsa-let-7d-5p, hsa-let-7f.-
5p) (Fig. 5a). On the other hand, community C3 has 765 elements: 15 miRNAs and 765 CpG sites including 
CpG probes with increased DNA methylation in HC (DAPP1, STIM1, PDEA4 and TOX2) and 4 miRNAs with 
increased expression in HC (Fig. 1b & Fig. 3). Overall, communities C3 and C5 reflect the antagonistic behavior 
that we had observed in HC and AD patients (Fig. 1b). Detailed information on the CpG sites and miRNAs 
detected in each community is presented in Supplementary Table S3 online.
The list of miRNAs targets together with the genes annotated to contain CpG sites associated with each com-
munity were further functionally characterized (Supplementary Table S4 online). Community 5 (C5) showed 
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Figure 1.  Differentially methylated probes (DMPs) in peripheral blood T cells between AD patients and HC. 
(a) Venn diagram showing the overlap of DMPs in four different sorted T cell populations. Plotted with the open 
webtool venny 2.0 (https ://bioin fogp.cnb.csic.es/tools /venny /). (b) Representative flow cytometry analysis of 
CD3, CLA, CD45RO and CCR4 in sorted  CD4+CLA+ T cells. Numbers within quadrants represent percentage 
of cells. FSC-H: forward scatter height; in histogram solid black line: unstained; dotted line: isotype control; 
gray line: anti CCR4 staining. (c) Eight DMPs in  CD4+CLA+ T cells. DNA methylation levels are expressed as 
M-values, gray bars indicate mean (bold), upper and lower (thin) quartiles. M values above 1 represent that the 
CpG site is methylated, and M values below − 1 represent that the CpG site is demethylated. Each dot represents 
an individual, HC (n = 9) and AD patients (n = 10).  PBH = Benjamini Hochberg p value.
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Table 2.  Annotated list of the 49 differentially methylated probes (DMPs) in  CD4+CLA+ cells of AD patients. 
chr = chromosome. pos = genome coordinate (hg19); DHS = DNAse hypersensitivity site. logfc = difference 










Decreased DNA methylation in AD patients
cg06460587 chr6 31650930 (−) Island Yes −1.38 3.75E−06 0.035
cg24531977 chr5 56204891 (+) C5orf35 N_Shore −1.14 2.46E−06 0.032
cg24690709 chr4 100768712 (+) DAPP1 OpenSea −1.03 6.73E−08 0.0029
cg26077005 chr6 27236793 (+) OpenSea −0.99 1.85E−07 0.0062
cg04853218 chr14 55769688 (+) FBXO34 OpenSea Yes −0.94 1.01E−09 9.94E−05
cg08214808 chr11 45922166 (−) MAPK8IP1 Island −0.91 2.13E−06 0.031
cg11770323 chr13 80066032 (+) NDFIP2 OpenSea Yes −0.90 4.18E−08 0.0020
cg21022949 chr2 231809697(+) OpenSea −0.88 5.38E−07 0.011
cg07182616 chr14 33409812 (+) NPAS3 OpenSea −0.87 3.34E−06 0.034
cg13782615 chr11 4079556 (+) STIM1 OpenSea Yes −0.86 2.48E−06 0.032
cg00726151 chr14 97881274 (−) OpenSea Yes −0.80 3.26E−11 6.50E−06
cg06854264 chr1 200861254 (+) C1orf106 S_Shore Yes −0.76 3.23E−06 0.034
cg03207915 chr6 119669112 (+) MAN1A1 N_Shore −0.76 2.57E−06 0.032
cg01436550 chr16 24781512 (+) TNRC6A OpenSea Yes −0.75 3.42E−06 0.034
cg12741231 chr8 19321936 (−) CSGALNACT1 S_Shelf −0.73 1.14E−10 1.51E−05
cg07343739 chrX 46617524 (+) SLC9A7 N_Shore Yes −0.72 2.37E−06 0.032
cg05313153 chr8 119122430 (+) EXT1 N_Shore −0.71 3.92E−07 0.0097
cg07633835 chr10 5938186 (−) FBXO18 OpenSea Yes −0.70 3.48E−06 0.034
cg25360385 chr12 51786547 (−) GALNT6 S_Shore −0.70 3.05E−06 0.034
cg19722656 chr6 119669372 (−) MAN1A1 N_Shore −0.67 1.01E−06 0.018
cg26780915 chr7 105519144 (+) S_Shore Yes −0.66 1.25E−09 9.94E−05
cg03405260 chr17 77786344 (+) Island −0.65 5.10E−06 0.043
cg10900455 chr20 42545099 (−) TOX2 Island Yes −0.65 7.91E−07 0.015
cg08416875 chr6 119669226 (−) MAN1A1 N_Shore −0.64 4.10E−06 0.037
cg13607082 chr12 122652224 (−) LRRC43 OpenSea −0.64 3.59E−07 0.0095
cg15447017 chr1 156095882 (+) LMNA OpenSea −0.63 3.49E−07 0.0095
cg12454975 chrX 103356930 (−) MCART6/ZCCHC18 N_Shore Yes −0.63 9.12E−07 0.017
cg08062822 chrX 103356845 (−) MCART6/ZCCHC18 N_Shore Yes −0.62 2.49E−06 0.032
cg12186909 chr19 10533016 (−) PDE4A S_Shore −0.57 3.10E−06 0.034
cg12589298 chr19 50828905 (−) KCNC3 Island −0.57 2.74E−06 0.033
cg07910680 chr18 56296449 (+) ALPK2 OpenSea Yes −0.55 5.41E−06 0.044
cg08494390 chr4 87980297 (−) AFF1 OpenSea Yes −0.54 5.90E−06 0.047
cg03403880 chr2 157255372 (−) N_Shore −0.52 2.66E−07 0.0081
cg14523284 chr5 131993614 (−) IL13 S_Shore −0.49 3.94E−06 0.036
cg02712553 chr10 64136038 (−) ZNF365 S_Shore −0.49 1.90E−06 0.029
cg17347326 chr17 77779426 (+) S_Shore Yes −0.46 3.39E−08 0.0019
cg05649724 chr14 102415204 (−) Island −0.45 4.61E−07 0.010
Increased DNA methylation in AD patients
cg16312212 chr8 18941574 (+) OpenSea Yes 3.23 1.73E−06 0.027
cg00211609 chr1 1178039 (−) FAM132A Island 1.26 5.28E−09 0.00035
cg04871131 chr7 94954202 (+) PON1 S_Shore Yes 1.01 1.09E−06 0.018
cg20595271 chr12 111889200 (+) SH2B3 OpenSea 0.85 8.71E−08 0.0034
cg00839873 chr14 94421989 (−) ASB2 OpenSea 0.77 3.64E−06 0.035
cg18482892 chr3 56833426 (−) ARHGEF3 N_Shelf 0.73 4.46E−06 0.039
cg01956154 chr14 94423399 (−) ASB2 OpenSea Yes 0.71 5.00E−14 1.99E−08
cg26800893 chr11 67184596 (−) ATPGD1 S_Shore Yes 0.68 1.89E−07 0.0062
cg08943180 chr1 244516022 (+) C1orf100 OpenSea 0.59 5.15E−06 0.043
cg05523877 chr10 72185663 (+) EIF4EBP2 OpenSea 0.53 1.53E−06 0.025
cg01697865 chr11 117856007 (+) IL10RA N_Shore 0.53 5.23E−07 0.011
cg21786381 chr11 75234078 (−) GDPD5 N_Shelf 0.48 3.11E−06 0.034
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many processes related to cell signaling. Indeed, top pathways (FDR < 10−8) associated with community C5 
revealed 17 involved in protein ubiquitination, positive regulation of intracellular signal transduction, protein 
phosphorylation, positive regulation of IKK/NFkB signaling, Ras protein signal transduction, stress-activated 
MAPK cascade and cytokine-mediated signaling (Fig. 5b). Overall, this suggests that epigenetic alterations in 
 CD4+CLA+ T cells of AD patients may be affecting receptors and adaptors that are crucial for the regulation of 
cytokine signaling. Genes that showed increased DNA methylation in AD were represented in these pathways, 
and included ASB2 in protein ubiquitination, IL10RA in cytokine mediated signaling and ESR1 as a common 
gene in several C5 pathways (Fig. 5b).
Discussion
Several studies have shown disturbed biology in skin homing  CLA+ T cells in AD patients but the underlying 
mechanisms explaining the alterations in this cell population remain unclear. We here analyzed the combined 
profiles of DNA methylation and miRNA expression in sorted peripheral blood T cell populations from AD 
patients compared to HC. This study revealed for the first-time significant differences in the DNA methylation 
levels of several key immune genes in skin homing  CD4+CLA+ T cells from AD patients. The most significant 
differences among the 40 differentially methylated genes were found in ASB2, DAPP1, FBXO34 and NDFIP2 
(Table 2). We also found significant DNA methylation differences in genes known to be genetically associated 
with AD predisposition including IL1339,40, IL10RA41, ZNF36542 and STIM143.
Our results revealed for the first time a significant inverse correlation between reduced DNA methylation in 
the IL13 promoter and increased IL13 mRNA expression in  CD4+CLA+ T cells of AD patients (Fig. 2c), providing 
insights into the molecular events that might lead to the remarkable ability of  CLA+ T cells from AD patients to 
secrete IL-1322,24,44. The relationship between reduced DNA methylation in the IL13 promoter of AD patients 
and increased IL-13 expression support that this cytokine is a central pathogenic mediator in  AD45 and thera-
pies targeting this molecule or its receptors (e.g. Dupilumab) might be beneficial in patients with severe atopic 
 phenotypes46. The increased DNA methylation levels in the IL13 promoter observed in HC could explain why 
the IL13 mRNA expression was significantly reduced in this group (Fig. 2). DNA methylation differences in the 
IL13 gene (cg04303330) has been also described by Boorgula et al., in whole blood samples from patients with 
the phenotype of AD with eczema  herpeticum47.
We also found reduced methylation in the gene PDE4A in AD patients, a molecule that promotes downstream 
inflammatory pathways and is amenable to be targeted with phosphodiesterase inhibitors (Fig. 1b)48. Since  CLA+ 
T cells recirculate between skin and blood and mediate pathogenic inflammation, antibodies targeting adhesion 
molecules used by  CLA+ T cells to mediate their transendothelial  migration49 or anti-CLA antibodies are being 
attempted and proposed as promising therapeutic options in  AD50. However, more studies are needed because 
 CLA+ T cells are involved in immunosurveillance and preventing their migration to skin produces  CLA+ leuko-
cytosis and possibly alterations in other tissues.
We discovered 16 miRNAs to be differently expressed in  CD4+CLA+ T cells from AD patients (Fig. 3), all 
except for miR-21 previously undescribed in  AD12. The magnitude of the expression differences between patients 
and controls was small, but the effect sizes for miRNA variation are unknown. The up-regulation of miR-21 and 
miR-145 may reflect the pro-inflammatory status of  CD4+  CLA+ T cells in AD patients. Indeed, miR-21 is involved 
in the polarization of adaptive immune responses and has been found upregulated in lesional skin biopsies of AD 
patients and in lesional skin of patients with contact dermatitis after challenge with  diphenylcyclopropenone51. 
The altered miRNA signatures in AD may differ depending on the cell type or tissue studied. We did not find 
Table 3.  Differentially methylated regions (DMRs) with decreased DNA methylation in  CD4+CLA+ T cells 
from AD patients compared to HC. a DMR analysis is based on minfi to collapse connected DNA methylation 
probes by distance rules; width in base pairs. b Sites in ESR1 cg21157690, cg17264271, cg15543523, cg26089753, 
cg08884395, cg01715172, cg21608605, cg20627916, cg07671949, cg23164938, cg23165623, cg21614759, 
cg19411146, cg21950534, cg11813455, cg24900983, cg05171584, cg23467008, cg22839866, cg23009221, 
cg27316393, cg00655307, cg01777019. CpG sites indicated in bold were also found as differentially methylated 
CpG sites in the DMP analysis (see Table 2). Chr: chromosome.
Gene Chr DMR Start Widtha CpGs ID logfc p value
Benjamini–Hochberg  p 
value
GPR55 2
231,790,037 776 4 cg16382047 cg14254999 cg19827923 cg13531460 −0.45 5.1 × 10
−7 0.01
231,809,610 87 3 cg08840017cg25013095 cg21022949 −0.73 1.5 × 10
−8 0.0006
MAN1A1 6 119,669,112 260 4 cg03207915 cg08416875 cg02578070 cg19722656 −0.68 2.5 × 10
−8 0.0008
ESR1 6 152,126,895 1910 23 See  footnoteb −0.36 3.6 × 10−6 0.03
CDHR3 7
105,515,219 677 2 cg03619256cg20186907 −0.55 7.8 × 10
−7 0.01
105,518,489 655 2 cg00494287cg26780915 −0.68 3.6 × 10
−10 2.4 × 10 − 5




−0.53 1.8 × 10−6 0.02
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Table 4.  A summary of the 40 differentially methylated genes in  CD4+CLA+ T cells of AD patients compared 
to HC (including genes with DMPs and DMRs).
Gene symbol Gene name Cell location Function
AFF1 AF4/FMR2 family, member 1 Nucleus Transcription factor
ALPK2 Alpha-kinase 2 Nucleoplasm Kinase recognize phosphorylated peptides
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 Cytosol Guanine nucleotide exchange factor
ASB2 Ankyrin repeat and SOCS box containing 2 Cytosol? Protein polyubiquitination/proteasome degradation
ATPGD1 aka. CARNS1 Carnosine synthase 1 Unknown Synthesis of carnosine and homocarnosine
C1orf100 Chromosome 1 open reading frame 100 Unknown Uncharacterized protein 147aa 17kda
C1orf106 Chromosome 1 open reading frame 106 Unknown Uncharacterized protein 663aa 72.9kda
C5orf35 Chromosome 5 open reading frame 35 Unknown Uncharacterized protein 147aa 17kda
CDHR3 Cadherin related family member 3 Plasma membrane Calcium-dependent cell adhesion proteins
CSGALNACT1 Chondroitin sulfate N-acetylgalactosaminyltrans-ferase 1 Golgi Peptidoglycan glycosyltransferase activity
DAPP1 Dual adaptor of phosphotyrosine and 3-phospho-inositides Plasma membrane, cytosol PI3K signaling
EIF4EBP2 Eukaryotic translation initiation factor 4E binding protein 2 Unknown Bind eIF4E and inhibit translation initiation
ESR1 Estrogen receptor 1 Plasma membrane, cytosol and nucleus Ligand-activated transcription factor
EXT1 Exostosin 1 Transmembrane glycoprotein er Catalyzing the synthesis of heparan sulfate
C1QTNF12 Complement C1q tumor necrosis factor-related protein 12 Secreted protein extracellular PI3K-Akt signaling pathway
FBH1 F-box protein, helicase, 18 Nucleus Unwinds double-stranded DNA in a 3 to 5 direction
FBXO34 F-box protein 34 Nucleoplasm, cytoplasm Protein-ubiquitin ligases
GALNT6 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) Golgi
O-linked glycosylation, GalNAc to serine and threo-
nine residues on target proteins
GDPD5 Glycerophosphodiester phosphodiesterase domain containing 5 Plasma membrane? Cytosol?
Glycerol metabolism, osmotic regulation of cellular 
glycerophosphocholine
GPR55 G Protein-Coupled Receptor 55 Plasma membrane Signaling pathway
IL10RA Interleukin 10 receptor, alpha Plasma membrane Akt signalling, IL-10 receptor
IL13 Interleukin 13 Extracellular space – secreted Interleukin 13
KCNC3 Potassium voltage-gated channel, Shaw-related subfamily, member 3 Plasma membrane Voltage channel
LMNA Lamin A/C Nucleus/cytosol Nuclear assembly, chromatin organization, nuclear membrane
LRRC43 Leucine rich repeat containing protein 43 Unknown Unknown
MAN1A1 Mannosidase, alpha, class 1A, member 1 Golgi membrane/er/secreted? Maturation of Asn-linked oligosaccharides
MAPK8IP1 Mitogen-activated protein kinase 8 interacting protein 1 Endoplasmic reticulum/mitocondria MAPK signaling pathway and Akt Signaling
MCART6 aka. SLC25A53 Solute carrier family 25, member 53 Unknown Unknown
NCOR2 Nuclear receptor corepressor 2 Nucleus Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer
NDFIP2 Nedd4 family interacting protein 2 Endosome/golgi/ER Interacts with HECT domain-containing E3 ubiquitin-protein ligases
NPAS3 Neuronal PAS domain protein 3 Nucleus Transcription factor
PDE4A Phosphodiesterase 4A, cAMP-specific Plasma membrane/cytosol cellular responses to extracellular signals
PON1 Paraoxonase 1 Extracellular space – secreted Aryl-dialkyl phosphatase activity
SH2B3 SH2B adaptor protein 3 Cytosol SH2B adaptor family of proteins, signaling activities by growth factor and cytokine receptors
SLC9A7 Solute carrier family 9, subfamily A (NHE7, cation proton antiporter 7), member 7 Endosome and Golgi
pH homeostasis in organelles along the secretory and 
endocytic pathways
STIM1 Stromal interaction molecule 1 Cytoskeleton, plasma membrane, ER
Mediates  Ca2+ influx after depletion of intracellular 
 Ca2+ stores by gating of store-operated  Ca2+ influx 
channels (SOCs)
TNRC6A Trinucleotide repeat containing 6A Cytosol Post-transcriptional gene silencing through the RNA interference (RNAi) and microRNA pathways
TOX2 TOX high mobility group box family member 2 Nucleus Chromatin remodeling
ZCCHC18 Zinc finger, CCHC domain containing 18 Nucleus Nucleic acid binding, TF
ZNF365 Zinc finger protein 365 Cytoplasm, centrosome Regulation of mitosis?
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any differences in the expression of miR-146a or miR-155 between AD and HC, previously reported to be 
up-regulated in lesional skin biopsies of AD  patients52,53 consistent with that in those studies the significant 
differences were attributed to the keratinocytes. Moreover, we discovered 202 biological processes significantly 
enriched in targets of AD-associated miRNAs of which many were implicated in cell signaling, transforming 
growth factor beta production and interferon responses (Fig. 4). These analyses highlighted ESR1 as a target 
of several AD upregulated miRNAs, involved in several processes such as cell differentiation and migration, 
transforming growth factor beta receptor signaling pathway and T cell differentiation (Supplementary Table S2 
online); suggesting for the first time that this transcription factor is a dysregulated mediator of several putative 
disturbed pathways in  CLA+ T cells from AD patients. These observations are in line with recent studies showing 
that estrogen-responsive genes may influence IL-13 production in patients with eosinophilic  esophagitis54. We 
also evaluated putative targets of the dysregulated miRNAs in  CD4+CLA+ T cells, not only for genes expressed 
in  CD4+ T cells but using the entire miRTarBase targets, since these altered miRNAs may be released from the 
T cell and exert their effects on skin cells, endothelium or other immune cells.
The integrative network analysis of coordinated changes of DNA methylation and miRNA in  CD4+CLA+ T 
cells revealed several pathways and new candidate dysregulated genes for AD (Fig. 5b). These included ASB2 
a gene encoding the ankyrin-repeat suppressor of cytokine signaling (SOCS) box-containing protein 2, an E3 
ubiquitin ligase that promotes protein degradation by coupling SOCS proteins with the elongin BC complex and 
mediate the ubiquitination of Notch targets such as E2A and Janus kinase (Jak)  255 and  Jak356. ASB2 is known 
to be expressed in T helper 2 cells (Th2), is regulated by GATA3 and promotes Th2 phenotype in vivo57. Further 
studies are needed to elucidate the role of ASB2 in  CLA+ T cells from AD patients. In contrast, HC showed 
increased methylation in NDFIP2 a gene encoding for the Nedd4 Family Interacting Protein 2 which has been 
described to limit the cytokine signaling and expansion of effector Th2  cells58 by promoting degradation of JAK1, 
probably by ITCH- and NEDD4L-mediated  ubiquitination59. Two other genes from the F-box family (FBXO18 
and FBXO24) implicated in protein ubiquitination were found differentially methylated in AD patients (Table 2), 
altogether suggesting that genes implicated in protein ubiquitination are epigenetically altered in  CD4+CLA+ 
Figure 2.  Differential DNA methylation and mRNA levels in the IL13 gene in  CD4+CLA+ T cells between AD 
patients and HC. (a) DNA methylation levels for the DMP located at the IL13 promoter (cg14523284). Each 
dot represents an individual, HC (n = 9, circle) and AD patients (n = 10, triangle).  PBH = Benjamini Hochberg p 
value. (b) IL13 mRNA levels in  CD4+CLA+ T cells between HC (n = 7) and AD patients (n = 10) by qRT-PCR. 
Gray bars in the panels a and b indicate mean (bold), upper and lower (thin) quartiles. (c) Correlation between 
IL13 mRNA levels and IL13 DNA methylation levels. Lines of best fit are individually presented for AD (solid 
line, m < −2.5, p < 0.0005,  R2 > 0.82) and HC (dashed line, m = 0.5, p = 0.65,  R2 < 0.05). (d) Location of the CpG 
site cg14523284 at the promoter of IL13 within the T helper type 2 locus control region associated RNA at Chr 
5q31.1 (https ://genom e.ucsc.edu).
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T cells from AD patients, and may promote inflammation by altering signaling. Ubiquitin ligases also mediate 
inhibition of activation of induced cell death (AICD) and contribute to lymphocyte  accumulation60, therefore, 
altered epigenetic signatures in genes involved in protein ubiquitination may contribute to the resistance to 
apoptosis that acquires the  CLA+ T cells upon skin  infiltration25.
The coordinated epigenetic changes highlight several genes and pathways involved in intracellular signal-
ing and were consistently associated with AD features in the  CD4+CLA+ T cells from patients. These included 
cytokine-mediated signaling associated with IL10RA and its intracellular adaptor SH2B3 which constrains 
cytokine signals and might influence inflammatory immune responses in peripheral lymphoid  tissues61. Also, 
the Ras signaling transduction pathway implicating ARHGEF3; as well as positive regulation of IKK/NFKB 
signaling implicating NDFIP2 (Fig. 5b). Among genes in community C3, TOX2 showed increased methylation 
in HC (Fig. 1b & Fig. 5a); this transcription factor is being recognized as a regulator of T cell differentiation but 
further studies are needed to evaluate its role in  CLA+ T  cells62,63.
We analyzed  CD4+CD45RA+ naïve T cells since we hypothesized that epigenetic signatures predisposing to 
T cell dysregulation in AD patients may already be present at this cell stage before the effector or memory T 
helper cell differentiation. In agreement with Han et al.64, we found almost no differences in DNA methylation 
levels between  CD4+ naïve T cells from AD patients compared to HC (Fig. 1a); neither in the unfractionated 
 CD4+ T cells as described by Rodriguez et al.11, nor in  CD8+ T cells supporting that epigenetic alterations are 
principally detected in  CD4+CLA+ T cells. The  CD8+CLA+ T cells also have an important role in  AD65,66, although 
recent studies highlighted their pathogenic role in  psoriasis67. Further studies are needed to evaluate epigenetic 
signatures in the  CD8+CLA+ T cell populations in AD patients.
Provided that T cell turnover between skin and blood involves active de-homing from skin and migration 
through the lymph nodes and peripheral  circulation26, it is conceivable that  CD4+CLA+ T cells isolated from 
blood could be informative on pathogenic processes occurring in skin. It remains to be determined at which 
developmental state the  CD4+CLA+ T cells acquired these altered epigenetic signatures in AD patients. Most 
probably by signals received after antigen priming or during their recirculation within skin, lymph nodes and 
the peripheral blood. Exposure to environmental signals from the skin microbiome or allergens could also be 
involved. We do not know the TCR specificity of the  CD4+CLA+ T cells analyzed here but previous studies have 
shown that  CLA+ T cells in AD preferentially respond to allergens and Staphylococcal enterotoxin  B68.
We did not compare frequencies of  CLA+ T cells between AD patients and HC in peripheral circulation, 
however, in agreement with previous  reports25, we found abundant infiltrates of  CLA+ cells in the lesional skin 
biopsy specimens of the AD patients compared to HC (Fig. 6a-c), which were also dominated by  CD3+ and 
 CD4+ cells in consecutive sections (data not shown). Given the larger numbers of these epigenetically altered 
 CD4+CLA+ T cells in the skin of patients (Fig. 6b) and the recirculation of these cells, we hypothesize that the 
epigenetic alterations detected in  CLA+ T cells from peripheral blood promote pro-inflammatory functions in 
skin of patients and contribute to AD immunopathology (Fig. 6d). It should be noted that AD is a heterogeneous 
Figure 3.  Differentially expressed miRNAs in  CD4+CLA+ T cells between AD patients and HC. (a) Differential 
miRNA expression by miRNA microarray between HC (n = 9) and AD patients (n = 10). Fold expression 
of 16 miRNAs with significant differences between AD patients and HC (Benjamini Hochberg corrected 
p value < 0.05). Blue indicates downregulation and yellow indicates upregulation. Each row corresponds 
to a miRNA and each column to 1 sample. Black and red squares on the top indicate HC and AD samples, 
respectively. Six down-regulated and 10 up-regulated and miRNAs in AD patients are indicated to the right of 
the heatmap. Software used Glucore Omics Explorer (https ://www.qluco re.com/). (b)  Log2 miRNA levels from 
the microarray analysis between HC and AD patients. The array level indicates the amount of miRNA based on 
the fluorescence signal in the Cy3 channel.  PBH = Benjamini Hochberg p value. (c) ∆-Ct miRNA levels confirmed 
with qPCR between HC and AD patients. Gray bars in the panels B and C indicate mean (bold), upper and 
lower quartiles; each dot represents an individual.
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disease with different immunophenotypes in the cellular infiltrates, including not only Th2 inflammation but also 
other cell  populations69–71. We here included adult patients with a phenotype of severe AD (objective SCORAD 
above 40) and allergen specific IgE sensitization. Therefore, the epigenetic signatures detected in this study and 
their related genes may be associated with this phenotype of patients, and more research is needed to evaluate 
their implications in other AD cohorts.
Several methodological aspects add strength to this study. To avoid the confounding effects that cell hetero-
geneity has on the interpretation of epigenetic and expression studies, we analyzed sorted T cell populations in 
peripheral blood. In addition, we used a robust methodology that interrogated DNA methylation levels in ~ 450 
000 CpG sites through the genome and global miRNA expression in ~ 2000 miRNAs. At several loci, the mag-
nitude of the epigenetic differences between AD and HC were relatively small, yet statistically significant after 
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Figure 4.  Functional enrichment analysis on the targets of AD perturbed miRNAs (FDR < 0.05). On the right 
hand key biological processes are summarized by their similarity. The lines are proportional to the number of 
biological processes associated with targets of miRNAs that are upregulated (red) or downregulated (black) in 
AD patients. The complete list of 202 processes is presented in Supplementary Table S2 online. This circular 
layout was created with the free R package circlize (https ://cran.r-proje ct.org/web/packa ges/circl ize/index .html).
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correction by multiple testing. Several of the loci detected in the comparison between AD patients and HC 
(Fig. 1b & Table 2) showed coordinated changes when analyzed with a different algorithm for network analysis 
(Fig. 5a). Our study has also some limitations, to avoid the confounding effects of gender, we included only male 
AD patients that even though they were selected to be as much homogeneous as possible had some differences 
in their total serum IgE levels, AD severity and the presence of comorbidities such as asthma (Table 1). It is 
worth noting that a larger sample size would assist in identifying important biological signals in the etiology of 
AD. Due to the limitations in the amount of cells that were sorted per individual, we could only measure mRNA 
expression in few genes by TaqMan. We detected significant differences in IL13 expression, but we could not 
interrogate how the coordinated changes in miRNA and CpG methylation affects global gene expression. Nev-
ertheless, this study revealed new genes and biological processes that deserve to be further validated at mRNA 
Figure 5.  Integrated network analysis of miRNAs and CpG sites (CpGs) highlights coordinated epigenetic 
changes in  CD4+CLA+ T cells. (a) Based on the set of associated miRNAs and CpG sites (absolute Spearman 
ρ > 0.75, FDR < 0.001) we identified 6 communities (C1–C6) of highly interconnected miRNAs/CpGs. These 
shows coordinated expression patterns, with strong interconnections within but not between communities. 
Note that communities 3 (yellow) and 5 (blue) show many of the differential miRNAs/CpGs detected in HC and 
AD patients: CpG sites (black), miRNAs (shadow), and miRNAs targeting IL13 (with asterisk). The node size 
for each community is proportional to the number of elements in each community. Line thickness connecting 
the communities is proportional to the number of connections between them. Detailed information on these 
communities is presented in Supplementary Table S3 online. (b) Functional enrichment analysis on putative 
regulated targets revealed 17 key pathways associated with AD (community C5) and are indicated as blue circles. 
Genes highlighted in pink and yellow were also detected as differentially methylated in the comparison between 
AD patients and HC (Table 2). The networks were created in Cytoscape 3.7.2 (https ://cytos cape.org/).
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and protein levels in other cohorts of AD patients and functionally evaluated at the cellular level to dissect their 
role in AD pathogenesis.
In summary, we here discovered putative altered molecular pathways in circulating  CD4+CLA+ T cells from 
AD patients, involving disease-associated signatures in DNA methylation and miRNA levels. The identified loci 
highlight new candidates in AD, including genes mediating intracellular cell signaling and adaptor molecules of 
the IL-10/IL-13 interleukin signaling pathway as well as genes involved in protein ubiquitination. Our findings 
support epigenetic profiling as a valuable tool to uncover putative molecules participating in disease pathways. 
Further studies are needed to define the downstream effects of these epigenetic alterations in AD immunopathol-
ogy and evaluate if environmental signals at the target organ (e.g., skin microbiota) induce the detected epigenetic 
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Methods
Study population and samples. Twenty age-matched adult male individuals (10 AD patients and 10 
HC) were selected from a Swedish eczema  study72. All participants were asked to visit the Dermatology Unit 
at the Karolinska University Hospital in Solna and were examined by a dermatologist for their general physical 
conditions, in case of AD patients, also for the severity of the eczema. Afterwards, all provided a 450 ml blood 
donation (see below). The cases fulfilled the following inclusion criteria: (1) a physician-diagnosis of moderate 
or severe AD as determined by the objective Scoring Atopic Dermatitis index (SCORAD) (2) elevated levels of 
total plasma IgE > 122  kUA/L (ImmunoCAP, Thermo Fisher Scientific, Uppsala, Sweden), (3) positive allergen-
specific IgE > 0.35  kUA/L as determined by Phadiatop (Thermo Fisher, Uppsala, Sweden), and (4) besides AD, a 
clinical history of asthma and/or rhinitis. All AD patients had used topical corticosteroids at least 30 days before 
blood sampling. Controls were healthy individuals without clinical history of eczema, asthma or other allergic 
diseases and plasma IgE levels below 122  kUA/L. On the same day as the 450 ml blood donation, skin biopsies 
were obtained from AD patients (n = 5) and from HC (n = 5). Punch biopsies (4 mm) were taken under local 
anesthesia (Lidocaine 5 mg/ml with epinephrine 5 µg/mL, Astra, Södertälje, Sweden) from eczema lesions in the 
AD patients located in the popliteal fossa, upper/mid back or shoulders and healthy skin of HC from the low-
back (lumbar) region. The biopsies were snap-frozen on dry ice and stored at −80 °C until immunohistochemis-
try analysis (see below). This study was conducted in accordance with the Helsinki Declaration ethical principles 
for medical research and was approved by the Regional Ethical Review Board in Stockholm (Dnrs 04–593/1, 
2008/1122–32, 2010/754–32, and 2011/1051–31). All participants gave their written informed consent.
Isolation of T cell populations. A 450 ml blood donation was obtained at the Blood Transfusion Center 
Karolinska University Hospital and processed immediately for cell isolation. Peripheral blood mononuclear 
cells (PBMCs) were separated by density centrifugation on Ficoll-Paque Plus (GE Healthcare, Uppsala, Swe-
den) and then labeled for magnetic associated cell sorting (MACS) to obtain  CD4+ T cells and  CD8+ T cells, 
 CD4+CD45RA+ naïve T cells and skin-homing  CD4+CLA+ T cells (Miltenyi Biotec, Gladbach, Germany). Cell 
viability after sorting was > 90% in all populations (as determined by trypan blue exclusion) and the purity was 
examined by flow cytometry (see below). Two aliquots were stored at −80 °C: one containing 5 × 106 cells for 
DNA extraction as described  previously36 and another containing a maximum of 10 × 106 cells homogenized in 
QIAzol lysis reagent (Qiagen, Hilden, Germany) for total RNA extraction.
Flow cytometry. Cells were re-suspended in FACS buffer (0.1% BSA in PBS) at a final concentration of 
0.1 × 106 cells per tube. Fc-receptors were blocked with 1 µl of normal mouse serum (Dako A/S, Glostrup, Den-
mark) for 10 min at 4 °C. Optimized panels of fluorochrome-conjugated monoclonal antibodies (Supplementary 
Table S1 online) were added to the cells, in a final volume of 100 µl and incubated for 30 min at 4 °C. Every stain-
ing included the unstained sample and the corresponding panels of isotype controls to set the gates for positive 
and negative populations. In addition to the markers described in Supplementary Table S1 online, which were 
measured in all the sorted samples, we also analyzed the cell surface expression of CCR4 (HC = 1, AD = 1) to bet-
ter define the immunophenotype of the  CD4+CLA+ T cells during validation of the cell sorting protocol (PerCP 
Anti-human CD194 (CCR4), clone L291H4, mIgG1 κ. Biolegend). Data were acquired using a FACS Calibur 
(BD Biosciences, San Jose, CA, USA), to at least 5000 events per population and analyzed by FlowJo vX.0.7 
(FlowJo, LLC, Ashland, OR, USA).
DNA methylation analysis. Genomic DNA was extracted using the QIAamp DNA Mini kit (Qiagen) and 
DNA concentrations were assessed by Qubit and Nanodrop. DNA purity was evaluated by the A260/A280 ratio 
by Nanodrop. After diluting to normalize the concentrations the DNA samples were bisulfite treated using the 
EZ-96 DNA Methylation kit (Zymo Research Corp., Irvine, CA, USA) according to manufacturer’s instructions. 
Denatured bisulfite-treated DNA was amplified, fragmented and hybridized onto the Infinium HumanMethyla-
tion450 BeadChip (Illumina Inc., San Diego, CA, USA), following manufacturer’s instructions, at the Mutation 
Analysis Core Facility (Karolinska Institutet, Stockholm, Sweden). The .idat files for each sample obtained from 
Genome Studio were imported in R and read in using the minfi  package73 with the genome annotation based 
on GRCh37/hg19. A total of 77 samples were analyzed: 20  CD4+(HC = 10, AD = 10), 18  CD4+CD45RA+ naïve 
(HC = 8, AD = 10), 19  CD4+CLA+ cells (HC = 9, AD = 10), and 20  CD8+ (HC = 10, AD = 10). The data were nor-
malized using the subset-quantile within array normalization (Swan)  method74. The probes overlapping with 
known SNPs were removed, leaving 398 494 CpG sites for further analysis. Differentially methylated CpG sites 
between AD patients and controls were obtained using linear models (y ~ group + subject + age) and pairwise 
comparisons with empirical Bayes as implemented in limma75. DMRs were analyzed with the minfi  package73. 
All the CpG sites presented as having differential methylation between AD patients and HC had a p value < 0.05 
after Benjamini-Hochberg (BH) correction for multiple testing.
RNA isolation and miRNA measurements. mRNA and miRNA were obtained by phenol/chloroform 
extraction. RNA integrity was evaluated using the Nanochip kits in Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA) resulting in RIN values (mean ± SD) of 9.31 ± 0.38. miRNA levels were measured for 4774 
probes (representing 2006 human miRNAs, miRBase database release 19) using the SurePrint G3 (8 × 60 K) 
miRNA array (Agilent Technologies). The raw .txt files obtained from the Agilent feature extraction software 
were imported in R and analyzed with limma75. After quality check 71 samples remained for the analysis of differ-
ential miRNA expression: 17  CD4+ (HC = 8, AD = 9), 15  CD4+CD45RA+ naïve (HC = 6, AD = 9), 19  CD4+CLA+ 
(HC = 9, AD = 10) and 20  CD8+ (HC = 10, AD = 10). To ensure homogeneity of analytical strategy with the DNA 
methylation, the same statistical approach described above was also used to find differentially expressed miR-
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NAs. Experimentally validated human miRNA targets were determined through Ingenuity Pathway Analysis 
(IPA) (https ://www.ingen uity.com) and  miRTarBase76.
Network analysis. Association analyses were performed after removing features with null variance and 
based on the entire set of quantified miRNAs and a subset of DNA methylation probes as follows. The full DNA 
methylation set comprising > 398,000 probes was filtered by first determining CpG probe UCSC classifications 
for the Illumina 450 K manifest through the FDb.InfiniumMethylation.hg19 R package in R 3.6.1, and excluded 
if no gene association was identified (e.g. intergenic probes). Secondly, we selected the top varying CpG probes 
(FDR < 0.1, 1.44% top probes) based on the limma comparison of AD patients and HC. Association analyses 
were then performed on the resulting set of 455 miRNA and 4369 CpG probes by Spearman correlations. P 
values were corrected for multiple hypothesis testing considering Benjamin-Hochberg false discovery rates 
as indicated throughout. The resulting set of positively correlated interactions were processed through igraph 
(https ://igrap h.org/) in Python 3.7. Node communities were computed through the Leiden algorithm through 
modularity  optimization38 and antagonistic feature relationships were identified as described by Benfeitas et al77.
Functional annotation. Gene set enrichment analysis was performed for Gene Ontology Biological Pro-
cesses (2018) and KEGG 2019 pathways through the  Enrichr78 API in Python 3.7 and considering the entire set 
of possible miRNA target genes and CpG-associated genes as background, where applicable. GO terms were fur-
Figure 6.  Identification of  CLA+ cells in skin biopsies and epigenetic changes detected in circulating 
 CD4+CLA+ T cells from AD patients that might contribute to skin inflammation. A representative 
immunohistochemistry staining of the distribution of  CLA+ cells in skin biopsies from (a) a healthy control, 
(b) lesional skin from an AD patient, and (c), rat IgM used as isotype control. Scale bars represent 50 µm. 
(d) Circulating  CD4+CLA+ T cells from AD patients (light blue cell) show significant differences in DNA 
methylation and miRNA levels compared to  CD4+CLA+ T cells from HC (purple cell). The main differences 
were detected in the reduced DNA methylation of the IL13 gene, the increased expression of proinflammatory 
miRNAs and coordinated epigenetic changes in genes involved in protein ubiquitination and cytokine signaling 
in AD patients. Since these  CD4+CLA+ T cells can recirculate between skin and  blood25, these altered epigenetic 
marks might contribute to AD immunopathology.
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ther filtered for redundancy based on their similarity through  Revigo79. Associations with miRNA targets were 
plotted using circus through the R circlize  package80 and Cytoscape 3.7.2 (https ://cytos cape.org/).
qPCR validation of miRNA and mRNA expression in  CD4+CLA+ T cells. To validate differentially 
expressed miRNAs, cDNA was prepared from the total RNA of  CD4+CLA+ T cells (15 ng) from 10 AD patients 
and 9 HC (the same samples as used in the Agilent array) using the miRCURY LNA Universal RT micro-
RNA PCR kit (Exiqon A/S, Vedbaek, Denmark) according to the manufacturer’s protocol. miRNAs were ampli-
fied using the miRCURY LNA SYBR Green master mix and specific PCR primer sets for 8 miRNAs (Exiqon) 
according to the manufacturer’s instructions. SNORD44 (snRNA) was used as endogenous control as described 
 previously81. To validate mRNA targets, cDNA was prepared using the high capacity RNA to cDNA kit (Life 
Technologies) starting from 80 ng of total RNA from 8 HC and 10 AD patients. Gene expression levels (mRNA) 
were measured using validated Taqman probes (Applied Biosystems, Foster City, CA, USA) according to manu-
facturer’s instructions using beta-2 microglobulin (B2M) as the reference gene. Quantitative real-time PCR was 
performed in the Biorad CFX96 system (BioRad Inc., Hercules, CA, USA) with each sample in duplicate, and 
the gene expression data were exported from the DataAssist Software v3.01. Differential expression between AD 
patients and HC was calculated using the comparative Ct method. In brief, the average Ct value for each miRNA 
was subtracted from the Ct value of SNORD44 to obtain the delta-Ct. The comparisons of delta-Ct between AD 
patients and HC were calculated by unpaired t-tests and a p value < 0.05 was considered significant.
Immunohistochemistry. The frozen skin biopsy specimens were embedded in optimal cutting tempera-
ture compound and six µm thin sections were prepared in a microtome-cryostat, two sections per glass slide. The 
tissue architecture and degree of cell infiltrates were evaluated by hematoxylin and eosin staining. For the evalu-
ation of T cell markers, the sections were acetone fixed and stained using the avidin–biotin complex method 
(Vectastain Elite ABC-kit, Vector Laboratories, Burlingame, CA, USA) according to the manufacturer’s instruc-
tions with the following primary antibodies: anti-CLA (rat IgM, clone: HECA-452), anti-CD4 (mouse  IgG1, 
clone: SK3), anti-CD3 (mouse  IgG1, clone: SK7), all from BD Pharmingen (San Diego, CA, USA). Rat IgM (clone 
R4-22, BD Pharmingen) and mouse  IgG1 (clone MG1-45, Biolegend) were included in each staining as isotype 
controls. Biotinylated antibodies targeting rat IgM (clone G53-238, BD Pharmingen) and mouse  IgG1 (BA-2001, 
Vector Laboratories) were used as secondary antibodies. The sections were counterstained with hematoxylin.
Statistical analysis. Statistical approaches were chosen according to the diverse data types in this study 
and explained in their respective methods sections. Hypothesis testing was performed by considering the null 
hypothesis of the absence of an association between the compared variables. The associations were tested accord-
ing to the nature of the data: continuous vs continuous (Spearman rank correlation test); continuous vs cat-
egorical (t-test or Mann Whitney test according to data distribution). p values were corrected by the Benjamini–
Hochberg procedure for multiple testing and a value < 0.05 was considered statistically significant.
 Data availability
The authors declare that data supporting the findings of this study are available within the paper and its sup-
plementary information files. DNA methylation and miRNA levels are available from the corresponding authors 
on reasonable request.
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